packageSasanlimab

sasanlimab

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Sasanlimab, a PD-1 inhibitor monoclonal antibody, was investigated as a treatment for bladder cancer. It remains investigational; its European marketing authorisation application was withdrawn, so it is not an approved medicine.

Unverified — written by glm-5.3-flash from general knowledge (no Wikidata entry found) and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:sasanlimab
ATC codes:L01FF16
DrugBank:DB18849

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown